Abstract
Epidermal growth factor receptors belong to the ErbB family of receptor tyrosine kinases (TKs) involved in the proliferation of normal and malignant cells. EGFR has attracted considerable attention as a target for cancer therapy. The findings reported herein are believed to provide some novel insights into the design of effective drugs for the therapeutic treatment of EGFR-related cancers. In particular, it is shown using sophisticated computational tools in a systematic way that the affinity of a wide spectrum of thiazolo[4,5-d]pyrimidine analogs can be carefully tuned up by seeking the desired goal in the structural modifications of EGFR, such as single point mutations of the critical EGFR residues in the active site. It is also demonstrated that a large number of the small ligand molecules can be efficiently divided into subgroups of the structurally similar ligands and that every such a subgroup has its unique inhibitory activity signature. The protein engineering approach, as quite reproducible, is proposed to be a viable partner to experiment in addressing a variety of issues, including investigation of clinically important mutations, development of drug resistance, identification of the most promising anti-cancer drug candidates, etc.
Keywords: Activity, affinity, binding energy, cancer, drug design, EGFR, molecular docking, inhibition, single point mutation.
Medicinal Chemistry
Title:Inhibitory Activity Against Epidermal Growth Factor Receptor (EGFR) Based on Single Point Mutations of Active Site Residues
Volume: 10 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Activity, affinity, binding energy, cancer, drug design, EGFR, molecular docking, inhibition, single point mutation.
Abstract: Epidermal growth factor receptors belong to the ErbB family of receptor tyrosine kinases (TKs) involved in the proliferation of normal and malignant cells. EGFR has attracted considerable attention as a target for cancer therapy. The findings reported herein are believed to provide some novel insights into the design of effective drugs for the therapeutic treatment of EGFR-related cancers. In particular, it is shown using sophisticated computational tools in a systematic way that the affinity of a wide spectrum of thiazolo[4,5-d]pyrimidine analogs can be carefully tuned up by seeking the desired goal in the structural modifications of EGFR, such as single point mutations of the critical EGFR residues in the active site. It is also demonstrated that a large number of the small ligand molecules can be efficiently divided into subgroups of the structurally similar ligands and that every such a subgroup has its unique inhibitory activity signature. The protein engineering approach, as quite reproducible, is proposed to be a viable partner to experiment in addressing a variety of issues, including investigation of clinically important mutations, development of drug resistance, identification of the most promising anti-cancer drug candidates, etc.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Inhibitory Activity Against Epidermal Growth Factor Receptor (EGFR) Based on Single Point Mutations of Active Site Residues, Medicinal Chemistry 2014; 10 (3) . https://dx.doi.org/10.2174/157340641003140304143442
DOI https://dx.doi.org/10.2174/157340641003140304143442 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release
Current Medicinal Chemistry Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Localization Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines Predict Their Functional Importance
Current Molecular Medicine Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Autotaxin and Lysophosphatidic Acid Receptors as Novel Targets for the Radiosensitization of Tumor Vasculature in Non-Small Cell Lung Cancer
Current Angiogenesis (Discontinued) The Effect of ACT on Self-Esteem and Self-efficacy of Women with Breast Cancer in Iran
Current Women`s Health Reviews Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Towards Understanding the Roles of Prohibitins, Multi-Functional Regulator Proteins
Current Chemical Biology Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design Meet Our Editor-in-Chief
Clinical Cancer Drugs Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Targeting Mutant KRAS for Anticancer Therapy
Current Topics in Medicinal Chemistry Delivery of Bioactive Peptides and Proteins Across Oral (Buccal) Mucosa
Current Pharmaceutical Biotechnology Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews Improvements in Algorithms for Phenotype Inference: The NAT2 Example
Current Drug Metabolism